Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy

BACKGROUND: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), tafamidis reduces all-cause mortality and cardiovascular hospitalizations, and slows decline in quality-of-life compared with placebo. In May 2019, tafamidis received expedited approval from the US FDA as a breakthrough dru...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Circulation
Autori principali: Kazi, Dhruv S., Bellows, Brandon K., Baron, Suzanne J., Shen, Changyu, Cohen, David J., Spertus, John A., Yeh, Robert W., Arnold, Suzanne V., Sperry, Brett W., Maurer, Mathew S., Shah, Sanjiv J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156331/
https://ncbi.nlm.nih.gov/pubmed/32078382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi